Mesoblast (MESO) Stock Price, News & Analysis

+0.14 (+2.33%)
(As of 02:58 PM ET)
Today's Range
50-Day Range
52-Week Range
148,513 shs
Average Volume
1.82 million shs
Market Capitalization
$700.39 million
P/E Ratio
Dividend Yield
Price Target

Mesoblast MarketRank™ Stock Analysis

Analyst Rating
2.17 Rating Score
121.1% Upside
$13.67 Price Target
Short Interest
2.05% of Shares Sold Short
Dividend Strength
News Sentiment
0.23mentions of Mesoblast in the last 14 days
Based on 3 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($0.71) to ($0.60) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.77 out of 5 stars

Medical Sector

511th out of 909 stocks

Biological Products, Except Diagnostic Industry

79th out of 156 stocks

MESO stock logo

About Mesoblast Stock (NASDAQ:MESO)

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

MESO Stock Price History

MESO Stock News Headlines

Exposed: 10 CENT Crypto to Explode April 20th?
Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin
Mesoblast Limited: Back From The Dead
Exposed: 10 CENT Crypto to Explode April 20th?
Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin
Top ASX Stocks for this Month
Top ASX shares to buy in April 2024
Mesoblast Ltd LWB
MESO Jan 2025 0.500 call
MESO Oct 2024 2.000 call
MESO Jul 2024 2.000 put
See More Headlines
Receive MESO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Previous Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
6 Analysts


Pretax Margin


Sales & Book Value

Annual Sales
$7.50 million
Book Value
$6.16 per share


Free Float
Market Cap
$684.42 million
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Silviu Itescu FACP (Age 67)
    FACRA, FRACP, MBBS (Hons), Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director
    Comp: $738.74k
  • Dr. Eric A. Rose M.D. (Age 73)
    Chief Medical Officer & Executive Director
    Comp: $625.46k
  • Mr. Andrew Chaponnel B.Com.
    Interim Chief Finance Officer
  • Mr. Peter T. Howard B.Sc. (Age 56)
    L.L.B., LLB (Hons), General Counsel & Corporate Executive
  • Mr. Roger D. Brown BA
    Head of Spinal Orthopedic Disorders
  • Mr. Michael Schuster BSc (Age 47)
    M.B.A., MS, Head of Pharma Partnering
  • Ms. Geraldine Storton B.Sc.
    M.B.A., MMS, Head of Regulatory Affairs & Quality Management
  • Mr. Justin Horst B.S.
    Head of Manufacturing
  • Ms. Niva Sivakumar B.Com.
    L.L.B., Joint Company Secretary
  • Mr. Paul Hughes BPHARM
    Joint Company Secretary

MESO Stock Analysis - Frequently Asked Questions

Should I buy or sell Mesoblast stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mesoblast in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MESO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MESO, but not buy additional shares or sell existing shares.
View MESO analyst ratings
or view top-rated stocks.

What is Mesoblast's stock price target for 2024?

6 equities research analysts have issued 12 month price objectives for Mesoblast's stock. Their MESO share price targets range from $3.00 to $34.00. On average, they expect the company's share price to reach $13.67 in the next twelve months. This suggests a possible upside of 121.1% from the stock's current price.
View analysts price targets for MESO
or view top-rated stocks among Wall Street analysts.

How have MESO shares performed in 2024?

Mesoblast's stock was trading at $2.20 at the start of the year. Since then, MESO shares have increased by 180.9% and is now trading at $6.18.
View the best growth stocks for 2024 here

Are investors shorting Mesoblast?

Mesoblast saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 2,340,000 shares, an increase of 190.1% from the March 15th total of 806,500 shares. Based on an average trading volume of 2,140,000 shares, the days-to-cover ratio is currently 1.1 days.
View Mesoblast's Short Interest

When is Mesoblast's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 23rd 2024.
View our MESO earnings forecast

How were Mesoblast's earnings last quarter?

Mesoblast Limited (NASDAQ:MESO) released its earnings results on Wednesday, August, 30th. The company reported ($0.28) EPS for the quarter, topping analysts' consensus estimates of ($0.34) by $0.06. The company had revenue of $2.14 million for the quarter, compared to the consensus estimate of $2 million.

When did Mesoblast's stock split?

Mesoblast shares reverse split on Friday, January 5th 2024. The 1-2 reverse split was announced on Friday, January 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 50 shares after the split.

What other stocks do shareholders of Mesoblast own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mesoblast investors own include Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Exelixis (EXEL), CRISPR Therapeutics (CRSP), Novavax (NVAX), Micron Technology (MU), Vaxart (VXRT) and AbbVie (ABBV).

When did Mesoblast IPO?

Mesoblast (MESO) raised $69 million in an IPO on Friday, November 13th 2015. The company issued 5,700,000 shares at a price of $12.10 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.

Who are Mesoblast's major shareholders?

Mesoblast's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Penbrook Management LLC (0.11%) and Chapin Davis Inc. (0.01%).

How do I buy shares of Mesoblast?

Shares of MESO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MESO) was last updated on 4/24/2024 by Staff

From Our Partners